Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease

被引：35

作者：

Thaisrivongs, David K. ^{[1
]}

Miller, Steven P. ^{[1
]}

Molinaro, Carmela ^{[1
]}

Chen, Qinghao ^{[1
]}

Song, Zhiguo J. ^{[1
]}

Tan, Lushi ^{[1
]}

Chen, Lu ^{[3
]}

Chen, Wenyong ^{[1
]}

Lekhal, Azzeddine ^{[2
]}

Pulicare, Sarah K. ^{[2
]}

Xu, Yanke ^{[2
]}

机构：

[1] Merck Res Labs, Proc Chem, POB 2000, Rahway, NJ 07065 USA

[2] Merck Res Labs, Chem Engn Res & Dev, Proc Res & Dev, POB 2000, Rahway, NJ 07065 USA

[3] WuXi AppTec Shanghai Pharmaceut Co Ltd, 288 Fute Zhong Rd, Shanghai 200131, Peoples R China

来源：

ORGANIC LETTERS | 2016年 / 18卷 / 22期

关键词：

EFFICIENT COPPER CATALYST; ARYL HALIDES; AMIDATION; AMINES;

D O I：

10.1021/acs.orglett.6b01793

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

Verubecestat is an inhibitor of beta-secretase being evaluated for the treatment of Alzheimer's disease. The first generation route relies on an amide coupling with a functionalized aniline, the preparation of which introduces synthetic inefficiencies. The second-generation route replaces this with a copper-catalyzed C-N coupling, allowing for more direct access to the target. Other features of the new route include a diastereoselective Mannich-type addition into an Ellman sulfinyl ketimine and a late-stage guanidinylation.

引用

页码：5780 / 5783

页数：4

共 50 条

[31] BACE1 INHIBITION AS A THERAPEUTIC STRATEGY FOR ALZHEIMER'S DISEASE
Vassar, Robert
NEUROBIOLOGY OF AGING, 2014, 35 : S23 - S23
[32] Targeting the β secretase BACE1 for Alzheimer's disease therapy
Yan, Riqiang
Vassar, Robert
LANCET NEUROLOGY, 2014, 13 (03): : 319 - 329
[33] BACE1 inhibition as a therapeutic strategy for Alzheimer's disease
Vassar, Robert
Journal of Sport and Health Science, 2016, 5 (04) : 388 - 390
[34] BACE1 expression and activity: Relevance in Alzheimer's disease
Zacchetti, Daniele
Chieregatti, Evelina
Bettegazzi, Barbara
Mihailovich, Marija
Sousa, Vitor Lino
Grohovaz, Fabio
Meldolesi, Jacopo
NEURODEGENERATIVE DISEASES, 2007, 4 (2-3) : 117 - 126
[35] A promising, novel, and unique BACE1 inhibitor emerges in the quest to prevent Alzheimer's disease
Zakaria, Justyna A. Dobrowolska
Vassar, Robert J.
EMBO MOLECULAR MEDICINE, 2018, 10 (11)
[36] From BACE1 Inhibitor to Multifunctionality of Tryptoline and Tryptamine Triazole Derivatives for Alzheimer's Disease
Jiaranaikulwanitch, Jutamas
Govitrapong, Piyarat
Fokin, Valery V.
Vajragupta, Opa
MOLECULES, 2012, 17 (07): : 8312 - 8333
[37] The selective BACE1 inhibitor VIa reduces Aβ production in a mouse model of Alzheimer's disease
Cheng, Xiao-rui
Zhou, Yu
Gu, Wei
Nie, Ai-hua
Cheng, Jun-ping
Zhou, Wen-xia
Zhang, Yong-xiang
FASEB JOURNAL, 2014, 28 (01):
[38] Pyrrolidine-fused iminoheterocycles as BACE1 inhibitors for the treatment of Alzheimer's disease
Gilbert, Eric
Huang, Chunli
Stamford, Andrew
Cumming, Jared
Greenlee, William
Kennedy, Matthew
Parker, Eric
Kuvelkar, Reshma
Cox, Kathleen
Voight, Johannes
Strickland, Corey
Palamanda, Jairam
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
[39] BACE1 and BACE2: exclusion of allele association with Alzheimer's disease
Giannakopoulos, P
Herrmann, F
Gold, G
Bouras, C
Mulligan, R
Duriaux-Sail, G
Michon, A
Antonarakis, SE
Blouin, JL
EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 : 267 - 267
[40] Alzheimer disease: BACE1 branches out
Charlotte Schubert
Nature Medicine, 2006, 12 : 1123 - 1123

← 1 2 3 4 5 →